The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.
While the test is unlikely to be used as a diagnostic for the virus, it could be useful for identifying patients at high risk of developing severe disease.
The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.
